Recombinant bacillus Calmette-Guérin as a potential vector for preventive HIV type 1 vaccines.
In August 1997, the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) convened an expert working group to discuss current strategies for the development of HIV type 1 vaccines. Based on the recent findings of investigators from Japan's National Institute of Infectious Diseases (NIID) in Tokyo using recombinant bacillus Calmette-Guérin (rBCG) as a potential vectored vaccine for HIV, a recommendation was made that further work in this area is a priority. As a result, the working group reconvened in September 1998 to discuss the progress to date with this vaccine approach, as well as areas of related research to assess the feasibility of a BCG-vectored HIV vaccine. This report summarizes the discussions addressing the available scientific data on the potential use of rBCG as a vector for preventive HIV vaccines, the work necessary to move such candidate vaccines into Phase 1 clinical trials, and recommendations targeted at facilitating the long-term development of rBCG-vectored HIV vaccines.
Falk
L A
LA
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Rockville, Maryland 20852-1448, USA.
Goldenthal
K L
KL
Esparza
J
J
Aguado
M T
MT
Osmanov
S
S
Ballou
W R
WR
Beddows
S
S
Bhamarapravati
N
N
Biberfeld
G
G
Ferrari
G
G
Hoft
D
D
Honda
M
M
Jackson
A
A
Lu
Y
Y
Marchal
G
G
McKinney
J
J
Yamazaki
S
S
D016915:AIDS Vaccines / Q000276:immunology; D000818:Animals; D001500:BCG Vaccine / Q000276:immunology; D017321:Clinical Trials, Phase I as Topic; D005822:Genetic Vectors; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D014480:United Nations; D014614:Vaccines, Synthetic / Q000276:immunology; D014944:World Health Organization
D016915:AIDS Vaccines; D001500:BCG Vaccine; D014614:Vaccines, Synthetic